1letý cíl společnosti Midatech Pharma Plc

Jaká je hodnota metriky 1letý cíl společnosti Midatech Pharma Plc?

Hodnota metriky 1letý cíl společnosti Midatech Pharma Plc je GBX6,700 +35,633.33%

Jaká je definice metriky 1letý cíl?

1-letý cíl (1-year target) je analytiky předpokládaná cena akcie za rok od dnešního dne.

One year target is an estimate of a stock price for a point in time equal to a year from the current date. The price level most often reflects the collective opinion of different analysts on where the stock will be trading a year from now. For an analyst to identify an individual estimate, they have to project what a company’s business will look like in a year, typically focusing on revenue and other significant factors. They also consider the willingness of investors to pay a certain price. While the average or median recommendation may be predictive and reflect the actual future value, the results are usually not extremely successful.

Čemu se věnuje společnost Midatech Pharma Plc?

Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Firmy s metrikou 1letý cíl podobnou společnosti Midatech Pharma Plc